Genetic testing to predict how individuals will respond to common medicines should be implemented without delay to reduce the risk of side-effects and ensure that everyone is given the right drug at the right dose, experts have said.
About 6.5% of UK hospital admissions are caused by adverse drug reactions, while most prescription medicines only work on 30% to 50% of people. A significant part of this is due to genetics: almost 99% of people carry at least one genetic variation that affects their response to certain drugs, including commonly prescribed painkillers, heart disease drugs and antidepressants.
A new report, published by the British Pharmacological Society and the Royal College of Physicians, argues that many of these issues could be addressed through pharmacogenomic testing, which allows personalized prescribing according to people’s genes.
“The ultimate goal is to make pharmacogenomic prescribing a reality for everyone within the NHS, which will empower healthcare professionals to deliver better, more personalized care,” said Sir Munir Pirmohamed, a professor of pharmacology and therapeutics at the University of Liverpool, who chaired the report’s working party.
“The aim of pharmacogenomics is to make sure patients get the right drug, at the right dose, at the right time to be able to improve their outcomes, treat their symptoms, cure their disease and prevent side-effects.”
